Premium
Individual and Combined Effects of Peroxisome Proliferator‐Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers
Author(s) -
Wagner J. A.,
Larson P. J.,
Weiss S.,
Miller J. L.,
Doebber T. W.,
Wu M. S.,
Moller D. E.,
Gottesdiener K. M.
Publication year - 2005
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270004273136
Subject(s) - fenofibrate , rosiglitazone , endocrinology , medicine , adiponectin , lipid metabolism , chemistry , crossover study , peroxisome proliferator activated receptor , pioglitazone , placebo , pharmacology , type 2 diabetes , receptor , diabetes mellitus , insulin resistance , alternative medicine , pathology
This open‐label, randomized, placebo‐controlled, incomplete‐block, 3‐period crossover pilot study investigated the effects of peroxisome proliferator‐activated receptor α‐ and γ‐agonists on biomarkers of lipid and glucose metabolism in 12 nondiabetic subjects. Plasma samples were collected before and after each 14‐day treatment with placebo, fenofibrate (201 mg/d), rosiglitazone (4 mg twice daily), and combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily). Except for triglycerides ( P < .042) and free fatty acids ( P <.074), no significant interaction was demonstrated between fenofibrate and rosiglitazone; thus, the effect due to each drug alone was evaluated (presence/absence of drug). Fenofibrate significantly ( P < .050) increased lipoprotein lipase activity (35%) and decreased apolipoproteins B (13%) and C‐III (20%). Rosiglitazone significantly ( P < .050) decreased fasting glucose (7.3%) and increased apolipoprotein C‐III (19%) and adiponectin (137%). Fenofibrate and rosiglitazone also produced effects on triglyoerides and free fatty acids, but it was not possible to determine if these effects were synergistic in nature.